AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, will be integrated and newly branded as AGC Biologics.

AGC Biologics, a provider of clinical and commercial manufacturing of therapeutic proteins, will offer contract development and manufacturing services to its clients from their state-of-the-art facilities in Seattle, WA and Berkeley, CA in the U.S.; Copenhagen, Denmark; Heidelberg, Germany; Chiba, Japan; and Yokohama, Japan. The company said it will maintain and grow its global presence with microbial and mammalian capabilities, fulfilling early-phase through late-phase projects, both at small- and large-scale.

This announcement accompanies the appointment of Gustavo Mahler as president and chief executive officer of AGC Biologics. Dr. Mahler will be responsible for the strategic development and support of the company’s future growth.

Dr. Mahler brings more than 20 years of scientific and executive management experience. Since becoming president and chief executive officer of CMC Biologics in 2015, he has increased growth and profit, resulting in double-digit growth, and highlighting the company as one of the fastest growing contract development and manufacturing organizations (CDMOs) in the industry.

“The emergence of AGC Biologics as a global CDMO powerhouse further accentuates the strong commitment of our organization to ensure we meet the demands of this fast-growing market, while providing our clients with unparalleled innovative solutions,” said Hideyuki Kurata, chairman and general manager of AGC Lifescience General Division, AGC Chemicals, AGC Asahi Glass Company. “I’m incredibly pleased Dr. Mahler will continue to lead AGC Biologics. Under his leadership, I’m confident that we will achieve our goal of becoming the industry’s leading CDMO.”

Dr. Mahler said, “I’m thrilled at this opportunity to continue to lead this great organization. With our proven track record, I believe that we will clearly pave the way to a successful future, providing our clients solutions to their greatest development and manufacturing challenges, and enabling the delivery of breakthrough treatments to patients across the globe.”